Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 4, 2024, details a material definitive agreement entered into by Silo Pharma, Inc. (Nasdaq: SILO). The Company executed a securities purchase agreement with institutional investors to raise capital through a private placement. The transaction closed on June 6, 2024.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2 million (prior to deducting fees and expenses).
- Securities Issued:
- 883,395 shares of Common Stock at $2.18 per share.
- Pre-Funded Warrants to purchase 34,037 shares at $2.1799 per warrant (exercise price $0.0001).
- Warrants Issued to Investors: Unregistered Common Warrants to purchase one share per unit purchased, exercisable at $2.06 per share for five years.
- Placement Agent Fees:
- Cash fee: 7.5% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Warrant: To purchase up to 68,807 shares (7.5% of aggregate offering) at $2.725 per share.
- Expenses: $25,000 (non-accountable), $50,000 (legal/out-of-pocket), and $15,950 (clearing fees).
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Restrictions
The filing does not provide comparative financial metrics (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement. Material changes include:
- Capital Structure: Immediate increase in outstanding shares and potential dilution from warrant exercises.
- Lock-Up Agreements: Executive officers and directors are restricted from disposing of or hedging shares for 15 days post-closing.
- Issuance Restrictions: The Company is prohibited from issuing new equity or entering into Variable Rate Transactions for 15 days post-closing (issuance) and one year post-closing (Variable Rate Transactions), subject to exceptions.
Outlook, Risks, and Contingencies
Management intends to utilize the net proceeds to fund working capital and general corporate needs. The filing notes that representations and warranties in the Purchase Agreement are for risk allocation between parties and may not reflect current facts or materiality standards for stockholders. The Company is obligated to file a resale registration statement (Form S-3) within 45 days of the agreement date and use commercially reasonable efforts to have it declared effective within 60 days thereafter.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8.5% cash fees and fixed expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and exceptions to the lock-up and issuance restrictions.
- Monitor the status of the Resale Registration Statement for the Common Warrant Shares to ensure liquidity for investors.
- Assess the dilution impact of the 883,395 shares sold plus the 34,037 pre-funded warrants and the 68,807 placement agent warrants.